Actively Recruiting
Real-world Studies of CDK4/6 Inhibitors
Led by Tianjin Medical University Cancer Institute and Hospital · Updated on 2026-02-12
245
Participants Needed
1
Research Sites
104 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
A single-center, real-world study evaluated the clinical outcomes and safety of CDK4/6 inhibitors combined with endocrine therapy in HR+/HER2- advanced breast cancer, and conducted a summary analysis of the clinical treatment options after the progression of CDK4/6 inhibitors.
CONDITIONS
Official Title
Real-world Studies of CDK4/6 Inhibitors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Diagnosed with HR+/HER2- advanced breast cancer per ASCO/CAP guidelines
- Treated at the study hospital between March 2022 and March 2025
- Received CDK4/6 inhibitors (e.g., palbociclib, abemaciclib, ribociclib, dalpiciclib) as advanced-stage treatment for at least one cycle
- Have complete medical history records including demographics, pathology, treatments, labs, and imaging
You will not qualify if you...
- Incomplete medical history data
- Only received CDK4/6 inhibitor monotherapy
- Received CDK4/6 inhibitors as neoadjuvant or postoperative adjuvant intensification therapy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Tianjin Medical University Cancer Insititute and Hospital
Tianjin, China, 300060
Actively Recruiting
Research Team
Y
Yehui Shi, MD
CONTACT
Y
Yiran Si, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
5
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here